Pallidone Palmitate API

Name	Pallidone palmitate
Chinese name	棕榈酸帕利哌酮
Cas Number	56238-63-2
Source	Europe
Qualifications	USDMF/-/-/-/-

Paliperidone palmitate was developed by Johnson & Johnson and was approved by the US FDA in December 2006. It is a long-acting injection of the second-generation antipsychotic paliperidone and the first approved for the treatment of mental illness in 2003. A new drug for schizophrenia is the main metabolite of risperidone. The mechanism of action of paliperidone is mediated by the combined action of central dopamine 2 (D2) receptors and 5-hydroxytryptamine (5HT2A) receptors. In addition, paliperidone is also α1 and α2 adrenergic receptors and Antagonist of H1 histamine receptor. Paliperidone palmitate can effectively overcome the time lag barrier of other long-acting antipsychotics, and can be used for both the acute and maintenance phases of schizophrenia. In addition, paliperidone does not cause extensive metabolism in the liver, and is secreted in large quantities through the kidneys without changes. It has the characteristics of side effects such as involuntary movements or tremors that are unique to atypical schizophrenia drugs. It is superior to the traditional drug olanzapine in terms of drug resistance and drug resistance. At the same time, there are fewer metabolic disorders, so it has good application prospects. In 2017, the global sales of paliperidone palmitate reached 3.2 billion U.S. dollars, of which China’s sales were 46.4 million yuan. The domestic market has a very bright prospect.

Hot Tags: pallidone palmitate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Ranolazine API, Vinpocetine API, Vardenafil API, Oseltamivir Phosphate API, Perindopril Arginine API, Gabapentin API

• Previous: Fimasartan Potassium API
• Next: Droxidopa API